Overview

Dabigatran Versus Warfarin After Mitral and/or Aortic Bioprosthesis Replacement and Atrial Fibrillation Postoperatively

Status:
Terminated
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
DAWA is a phase 2, prospective, open-label, randomized, pilot study. The main variable to be observed in this study is intracardiac thrombus. There are no formal primary or secondary clinical efficacy or safety outcomes because it is a pilot study.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Hospital Ana Nery
Treatments:
Dabigatran
Warfarin